Mechanisms and pathways of innate immune activation and regulation in health and cancer

Human Vaccines and Immunotherapeutics

Volumn 10, Issue 11, 2014, Pages 3270-3285

  Cui, Jun ^a   Chen, Yongjun ^a   Wang, Helen Y ^b   Wang, Rong Fu ^b  

^a SUN YAT SEN UNIVERSITY   (China)

^b HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

Author keywords

Cancer; Inflammation; Innate immunity; PRRs; Type I interferon

Indexed keywords

CASPASE RECRUITMENT DOMAIN PROTEIN 15; CASPASE RECRUITMENT DOMAIN PROTEIN 4; DEUBIQUITINASE; INFLAMMASOME; INTERFERON; INTERFERON REGULATORY FACTOR 3; INTERFERON REGULATORY FACTOR 7; MEMBRANE PROTEIN; PATTERN RECOGNITION RECEPTOR; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 3; UBIQUITIN PROTEIN LIGASE E3; DNA VIRUS;

ARTICLE; BACTERIAL IMMUNITY; DNA VIRUS; HOST PATHOGEN INTERACTION; HUMAN; IMMUNOREGULATION; INNATE IMMUNITY; NONHUMAN; PROTEIN FUNCTION; RNA VIRUS; SIGNAL TRANSDUCTION; TUMOR IMMUNITY; IMMUNOLOGY; NEOPLASM;

DNA VIRUSES; HUMANS; IMMUNITY, INNATE; INFLAMMASOMES; INTERFERON TYPE I; NEOPLASMS; RNA VIRUSES; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS;

EID: 84921752408     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/21645515.2014.979640     Document Type: Article

References (222)

1. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006; 124:783-801; PMID:16497588; http://dx.doi.org/10.1016/j.cell.2006.02.015
2. Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell 2010; 140:805-20; PMID:20303872; http://dx.doi.org/10.1016/j.cell.2010.01.022
3. Paludan SR, Bowie AG. Immune sensing of DNA. Immunity 2013; 38:870-80; PMID:23706668; http://dx.doi.org/10.1016/j.immuni.2013.05.004
4. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004;5:987-95; PMID:15454922; http://dx.doi.org/10.1038/ni1112
5. Takeda K, Akira S. Toll-like receptors in innate immunity. Int Immunol 2005; 17:1-14; PMID:15585605; http://dx.doi.org/10.1093/intimm/ dxh186
6. Basith S, Manavalan B, Yoo TH, Kim SG, Choi S. Roles of toll-like receptors in cancer: a double-edged sword for defense and offense. Arch Pharm Res 2012;35:1297-316; PMID:22941474; http://dx.doi.org/10.1007/s12272-012-0802-7
7. Hoving JC,Wilson GJ, Brown GD. Signalling C-type lectin receptors, microbial recognition and immunity. Cell Microbiol 2014; 16:185-94; PMID:24330199; http://dx.doi.org/10.1111/cmi.12249
8. Drummond RA, Brown GD. Signalling C-type lectins in antimicrobial immunity. PLoS Pathog 2013;9:e1003417; PMID:23935480; http://dx.doi.org/10.1371/journal.ppat.1003417
9. Geijtenbeek TB, Gringhuis SI. Signalling through Ctype lectin receptors: shaping immune responses. Nat Rev Immunol 2009; 9:465-79; PMID:19521399; http://dx.doi.org/10.1038/nri2569
10. Meylan E, Tschopp J, Karin M. Intracellular pattern recognition receptors in the host response. Nature 2006; 442:39-44; PMID:16823444; http://dx.doi. org/10.1038/nature04946
11. Elinav E, Strowig T, Henao-Mejia J, Flavell RA. Regulation of the antimicrobial response by NLR proteins. Immunity 2011; 34:665-79; PMID:21616436; http://dx.doi.org/10.1016/j.immuni.2011.05.007
12. Goubau D, Deddouche S, Reis e Sousa C. Cytosolic sensing of viruses. Immunity 2013; 38:855-69; PMID:23706667; http://dx.doi.org/10.1016/j.immuni.2013.05.007
13. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol 2003; 21:335-76; PMID:12524386; http://dx.doi.org/10.1146/annurev.immunol.21.120601.141126
14. Kawai T, Akira S. Signaling to NF-kappaB by Toll-like receptors. Trends Mol Med 2007; 13:460-9; PMID:18029230; http://dx.doi.org/10.1016/j.molmed.2007.09.002
15. Lund JM, Alexopoulou L, Sato A, Karow M, Adams NC, Gale NW, Iwasaki A, Flavell RA. Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc Natl Acad Sci U S A 2004; 101:5598-603; PMID:15034168; http://dx.doi.org/10.1073/pnas.0400937101
16. Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, Akira S, Lipford G, Wagner H, Bauer S. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 2004;303:1526-9; PMID:14976262; http://dx.doi.org/10.1126/science.1093620
17. Peng G, Guo Z, Kiniwa Y, Voo KS, Peng W, Fu T, Wang DY, Li Y, Wang HY, Wang RF. Toll-like receptor 8-mediated reversal of CD4 C regulatory T cell function. Science 2005; 309:1380-4; PMID:16123302; http://dx.doi.org/10.1126/science.1113401
18. O'Neill LA, Fitzgerald KA, Bowie AG. The Toll-IL-1 receptor adaptor family grows to five members. Trends Immunol 2003; 24:286-90; PMID:12810098
19. Uematsu S, Akira S. Toll-like receptors and innate immunity. J Mol Med (Berl) 2006; 84:712-25; PMID:16924467; http://dx.doi.org/10.1007/s00109-006-0084-y
20. West AP, Koblansky AA, Ghosh S. Recognition and signaling by toll-like receptors. Annu Rev Cell Dev Biol 2006; 22:409-37; PMID:16822173; http://dx. doi.org/10.1146/annurev.cellbio.21.122303.115827
21. Deng L,Wang C, Spencer E, Yang L, Braun A, You J, Slaughter C, Pickart C, Chen ZJ. Activation of the IkappaB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell 2000; 103:351-61; PMID:11057907
22. Wang C, Deng L, Hong M, Akkaraju GR, Inoue J, Chen ZJ. TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature 2001; 412:346-51; PMID:11460167; http://dx.doi.org/10.1038/35085597
23. Li S, Strelow A, Fontana EJ, Wesche H. IRAK-4: a novel member of the IRAK family with the properties of an IRAK-kinase. Proc Natl Acad Sci U S A 2002;99:5567-72; PMID:11960013; http://dx.doi.org/10.1073/pnas.082100399
24. Hayden MS, Ghosh S. Shared principles in NF-kappaB signaling. Cell 2008; 132:344-62; PMID:18267068; http://dx.doi.org/10.1016/j.cell.2008.01.020
25. Honda K, Ohba Y, Yanai H, Negishi H, Mizutani T, Takaoka A, Taya C, Taniguchi T. Spatiotemporal regulation of MyD88-IRF-7 signalling for robust type-I interferon induction. Nature 2005; 434:1035-40; PMID:15815647; http://dx.doi.org/10.1038/nature03547
26. Takaoka A, Yanai H, Kondo S, Duncan G, Negishi H, Mizutani T, Kano S, Honda K, Ohba Y, Mak TW, et al. Integral role of IRF-5 in the gene induction programme activated by Toll-like receptors. Nature 2005; 434:243-9; PMID:15665823; http://dx.doi. org/10.1038/nature03308
27. Yamamoto M, Sato S, Hemmi H, Hoshino K, Kaisho T, Sanjo H, Takeuchi O, Sugiyama M, Okabe M, Takeda K, et al. Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science 2003; 301:640-3; PMID:12855817; http://dx.doi.org/10.1126/ science.1087262
28. Fritz JH, Ferrero RL, Philpott DJ, Girardin SE. Nodlike proteins in immunity, inflammation and disease. Nat Immunol 2006; 7:1250-7; PMID:17110941; http://dx.doi.org/10.1038/ni1412
29. Magalhaes JG, Sorbara MT, Girardin SE, Philpott DJ. What is new with Nods? Curr Opin Immunol 2011; 23:29-34; PMID:21190821; http://dx.doi.org/10.1016/j.coi.2010.12.003
30. Chen G, Shaw MH, Kim YG, Nunez G. NOD-like receptors: role in innate immunity and inflammatory disease. Annu Rev Pathol 2009; 4:365-98; PMID:18928408; http://dx.doi.org/10.1146/ annurev.pathol.4.110807.092239
31. Travassos LH, Carneiro LA, Ramjeet M, Hussey S, Kim YG, Magalhaes JG, Yuan L, Soares F, Chea E, Le Bourhis L, et al. Nod1 and Nod2 direct autophagy by recruiting ATG16L1 to the plasma membrane at the site of bacterial entry. Nat Immunol 2010; 11:55-62; PMID:19898471; http://dx.doi.org/10.1038/ni.1823
32. Cooney R, Baker J, Brain O, Danis B, Pichulik T, Allan P, Ferguson DJ, Campbell BJ, Jewell D, Simmons A. NOD2 stimulation induces autophagy in dendritic cells influencing bacterial handling and antigen presentation. Nat Med 2010; 16:90-7; PMID:19966812; http://dx.doi.org/10.1038/nm.2069
33. Sabbah A, Chang TH, Harnack R, Frohlich V, Tominaga K, Dube PH, Xiang Y, Bose S. Activation of innate immune antiviral responses by Nod2. Nat Immunol 2009; 10:1073-80; PMID:19701189; http://dx.doi.org/10.1038/ni.1782
34. Franchi L, Munoz-Planillo R, Nunez G. Sensing and reacting to microbes through the inflammasomes. Nat Immunol 2012; 13:325-32; PMID:22430785; http:// dx.doi.org/10.1038/ni.2231
35. Cai X, Chen J, Xu H, Liu S, Jiang QX, Halfmann R, Chen ZJ. Prion-like polymerization underlies signal transduction in antiviral immune defense and inflammasome activation. Cell 2014; 156:1207-22; PMID:24630723; http://dx.doi.org/10.1016/j.cell.2014.01.063
36. Lu A, Magupalli VG, Ruan J, Yin Q, Atianand MK, Vos MR, Schröder GF, Fitzgerald KA, Wu H, Egelman EH. Unified polymerization mechanism for the assembly of ASC-dependent inflammasomes. Cell 2014; 156:1193-206; PMID:24630722; http://dx. doi.org/10.1016/j.cell.2014.02.008
37. Jin T, Curry J, Smith P, Jiang J, Xiao TS. Structure of the NLRP1 caspase recruitment domain suggests potential mechanisms for its association with procaspase-1. Proteins 2013; 81:1266-70; PMID:23508996; http://dx.doi.org/10.1002/prot.24287
38. Faustin B, Lartigue L, Bruey JM, Luciano F, Sergienko E, Bailly-Maitre B, Volkmann N, Hanein D, Rouiller I, Reed JC. Reconstituted NALP1 inflammasome reveals two-step mechanism of caspase-1 activation. Mol Cell 2007; 25:713-24; PMID:17349957; http://dx.doi.org/10.1016/j.molcel.2007.01.032
39. Gregory SM, Davis BK, West JA, Taxman DJ,Matsuzawa S, Reed JC, Ting JP, Damania B. Discovery of a viral NLR homolog that inhibits the inflammasome. Science 2011; 331:330-4; PMID:21252346; http:// dx.doi.org/10.1126/science.1199478
40. Boyden ED, Dietrich WF. Nalp1b controls mouse macrophage susceptibility to anthrax lethal toxin. Nat Genet 2006; 38:240-4; PMID:16429160; http://dx. doi.org/10.1038/ng1724
41. Kofoed EM, Vance RE. Innate immune recognition of bacterial ligands by NAIPs determines inflammasome specificity. Nature 2011; 477:592-5; PMID:21874021; http://dx.doi.org/10.1038/nature10394
42. Zhao Y, Yang J, Shi J, Gong YN, Lu Q, Xu H, Liu L, Shao F. The NLRC4 inflammasome receptors for bacterial flagellin and type III secretion apparatus. Nature 2011; 477:596-600; PMID:21918512; http://dx.doi. org/10.1038/nature10510
43. Halff EF, Diebolder CA, Versteeg M, Schouten A, Brondijk TH, Huizinga EG. Formation and structure of a NAIP5-NLRC4 inflammasome induced by direct interactions with conserved N- and C-terminal regions of flagellin. J Biol Chem 2012; 287:38460-72; PMID:23012363; http://dx.doi.org/10.1074/jbc.M112.393512
44. Yang J, Zhao Y, Shi J, Shao F. Human NAIP and mouse NAIP1 recognize bacterial type III secretion needle protein for inflammasome activation. Proc Natl Acad Sci U S A 2013; 110:14408-13; PMID:23940371; http://dx.doi.org/10.1073/pnas.1306376110
45. Agostini L, Martinon F, Burns K, McDermott MF, Hawkins PN, Tschopp J. NALP3 forms an IL-1betaprocessing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity 2004; 20:319-25; PMID:15030775
46. Wen H, Miao EA, Ting JP. Mechanisms of NODlike receptor-associated inflammasome activation. Immunity 2013; 39:432-41; PMID:24054327; http://dx.doi.org/10.1016/j.immuni.2013.08.037
47. Latz E. The inflammasomes: mechanisms of activation and function. Curr Opin Immunol 2010; 22:28-33; PMID:20060699; http://dx.doi.org/10.1016/j.coi.2009.12.004
48. Mitoma H, Hanabuchi S, Kim T, Bao M, Zhang Z, Sugimoto N, Liu YJ. The DHX33 RNA helicase senses cytosolic RNA and activates the NLRP3 inflammasome. Immunity 2013; 39:123-35; PMID:23871209; http://dx.doi.org/10.1016/j.immuni.2013.07.001
49. Fernandes-Alnemri T, Yu JW, Datta P, Wu J, Alnemri ES. AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA. Nature 2009; 458:509-13; PMID:19158676; http://dx.doi. org/10.1038/nature07710
50. Hornung V, Ablasser A, Charrel-Dennis M, Bauernfeind F, Horvath G, Caffrey DR, Latz E, Fitzgerald KA. AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC. Nature 2009; 458:514-8; PMID:19158675; http://dx.doi. org/10.1038/nature07725
51. Roberts TL, Idris A, Dunn JA, Kelly GM, Burnton CM, Hodgson S, Hardy LL, Garceau V, Sweet MJ, Ross IL, et al. HIN-200 proteins regulate caspase activation in response to foreign cytoplasmic DNA. Science 2009; 323:1057-60; PMID:19131592; http:// dx.doi.org/10.1126/science.1169841
52. Burckstummer T, Baumann C, Bluml S, Dixit E, Durnberger G, Jahn H, Planyavsky M, Bilban M, Colinge J, Bennett KL, et al. An orthogonal proteo-mic-genomic screen identifies AIM2 as a cytoplasmic DNA sensor for the inflammasome. Nat Immunol 2009; 10:266-72; PMID:19158679; http://dx.doi. org/10.1038/ni.1702
53. Fernandes-Alnemri T, Yu JW, Juliana C, Solorzano L, Kang S, Wu J, Datta P, McCormick M, Huang L, McDermott E, et al. The AIM2 inflammasome is critical for innate immunity to Francisella tularensis. Nat Immunol 2010; 11:385-93; PMID:20351693; http:// dx.doi.org/10.1038/ni.1859
54. Rathinam VA, Jiang Z, Waggoner SN, Sharma S, Cole LE, Waggoner L, Vanaja SK, Monks BG, Ganesan S, Latz E, et al. The AIM2 inflammasome is essential for host defense against cytosolic bacteria and DNA viruses. Nat Immunol 2010; 11:395-402; PMID:20351692; http://dx.doi.org/10.1038/ni.1864
55. Loo YM, Gale M Jr. Immune signaling by RIG-Ilike receptors. Immunity 2011; 34:680-92; PMID:21616437; http://dx.doi.org/10.1016/j.immuni.2011.05.003
56. Xu LG, Wang YY, Han KJ, Li LY, Zhai Z, Shu HB. VISA is an adapter protein required for virus-triggered IFN-beta signaling. Mol Cell 2005; 19:727-40; PMID:16153868; http://dx.doi.org/10.1016/j.molcel.2005.08.014
57. Kawai T, Takahashi K, Sato S, Coban C, Kumar H, Kato H, Ishii KJ, Takeuchi O, Akira S. IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction. Nat Immunol 2005; 6:981-8; PMID:16127453; http://dx.doi.org/10.1038/ni1243
58. Seth RB, Sun L, Ea CK, Chen ZJ. Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-kappaB and IRF 3. Cell 2005; 122:669-82; PMID:16125763; http://dx. doi.org/10.1016/j.cell.2005.08.012
59. Meylan E, Curran J, Hofmann K, Moradpour D, Binder M, Bartenschlager R, Tschopp J. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 2005; 437:1167-72; PMID:16177806; http://dx.doi.org/10.1038/nature04193
60. Hou F, Sun L, Zheng H, Skaug B, Jiang QX, Chen ZJ. MAVS forms functional prion-like aggregates to activate and propagate antiviral innate immune response. Cell 2011; 146:448-61; PMID:21782231; http://dx.doi.org/10.1016/j.cell.2011.06.041
61. Saito T, Hirai R, Loo YM, Owen D, Johnson CL, Sinha SC, Akira S, Fujita T, Gale M Jr. Regulation of innate antiviral defenses through a shared repressor domain in RIG-I and LGP2. Proc Natl Acad Sci U S A 2007; 104:582-7; PMID:17190814; http://dx.doi. org/10.1073/pnas.0606699104
62. Satoh T, Kato H, Kumagai Y, Yoneyama M, Sato S, Matsushita K, Tsujimura T, Fujita T, Akira S, Takeuchi O. LGP2 is a positive regulator of RIG-I- and MDA5-mediated antiviral responses. Proc Natl Acad Sci U S A 2010; 107:1512-7; PMID:20080593; http://dx.doi.org/10.1073/pnas.0912986107
63. Takaoka A, Wang Z, Choi MK, Yanai H, Negishi H, Ban T, Lu Y, Miyagishi M, Kodama T, Honda K, Ohba Y, et al. DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response. Nature 2007; 448:501-5; PMID:17618271; http://dx.doi.org/10.1038/nature06013
64. DeFilippis VR, Alvarado D, Sali T, Rothenburg S, Fruh K. Human cytomegalovirus induces the interferon response via the DNA sensor ZBP1. J Virol 2010; 84:585-98; PMID:19846511; http://dx.doi. org/10.1128/JVI.01748-09
65. Ishii KJ, Kawagoe T, Koyama S, Matsui K, Kumar H, Kawai T, et al. TANK-binding kinase-1 delineates innate and adaptive immune responses to DNA vaccines. Nature 2008; 451:725-9; PMID:18256672; http://dx.doi.org/10.1038/nature06537
66. Chiu YH, Macmillan JB, Chen ZJ. RNA polymerase III detects cytosolic DNA and induces type I interferons through the RIG-I pathway. Cell 2009; 138:576-91; PMID:19631370; http://dx.doi.org/10.1016/j. cell.2009.06.015
67. Ablasser A, Bauernfeind F, Hartmann G, Latz E, Fitzgerald KA, Hornung V. RIG-I-dependent sensing of poly(dA:dT) through the induction of an RNA polymerase III-transcribed RNA intermediate. Nat Immunol 2009; 10:1065-72; PMID:19609254; http://dx. doi.org/10.1038/ni.1779
68. Zhang Z, Yuan B, Bao M, Lu N, Kim T, Liu YJ. The helicase DDX41 senses intracellular DNA mediated by the adaptor STING in dendritic cells. Nat Immunol 2011; 12:959-65; PMID:21892174; http://dx. doi.org/10.1038/ni.2091
69. Unterholzner L, Keating SE, Baran M, Horan KA, Jensen SB, Sharma S, Sirois CM, Jin T, Latz E, Xiao TS, et al. IFI16 is an innate immune sensor for intracellular DNA. Nat Immunol 2010; 11:997-1004; PMID:20890285; http://dx.doi.org/10.1038/ni.1932
70. Ishikawa H, Barber GN. STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature 2008; 455:674-8; PMID:18724357; http://dx.doi.org/10.1038/nature07317
71. Ishikawa H, Ma Z, Barber GN. STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity. Nature 2009; 461:788-92; PMID:19776740; http://dx.doi.org/10.1038/nature08476
72. McWhirter SM, Barbalat R, Monroe KM, Fontana MF, Hyodo M, Joncker NT, Ishii KJ, Akira S, Colonna M, Chen ZJ, et al. A host type I interferon response is induced by cytosolic sensing of the bacterial second messenger cyclic-di-GMP. J Exp Med 2009; 206:1899-911; PMID:19652017; http://dx. doi.org/10.1084/jem.20082874
73. Burdette DL, Monroe KM, Sotelo-Troha K, Iwig JS, Eckert B, Hyodo M, Hayakawa Y, Vance RE. STING is a direct innate immune sensor of cyclic di-GMP. Nature 2011; 478:515-8; PMID:21947006; http:// dx.doi.org/10.1038/nature10429
74. Wu J, Sun L, Chen X, Du F, Shi H, Chen C, Chen ZJ. Cyclic GMP-AMP is an endogenous second messenger in innate immune signaling by cytosolic DNA. Science 2013; 339:826-30; PMID:23258412; http:// dx.doi.org/10.1126/science.1229963
75. Sun L, Wu J, Du F, Chen X, Chen ZJ. Cyclic GMPAMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science 2013; 339:786-91; PMID:23258413; http://dx.doi.org/10.1126/ science.1232458
76. Liew FY, Xu D, Brint EK, O'Neill LA. Negative regulation of toll-like receptor-mediated immune responses. Nat Rev Immunol 2005; 5:446-58; PMID:15928677; http://dx.doi.org/10.1038/nri1630
77. Qian C, Cao X. Regulation of Toll-like receptor signaling pathways in innate immune responses. Ann N Y Acad Sci 2013; 1283:67-74; PMID:23163321; http://dx.doi.org/10.1111/j.1749-6632.2012.06786.x
78. Zanoni I, Ostuni R, Marek LR, Barresi S, Barbalat R, Barton GM, Granucci F, Kagan JC. CD14 controls the LPS-induced endocytosis of Toll-like receptor 4. Cell 2011; 147:868-80; PMID:22078883; http://dx. doi.org/10.1016/j.cell.2011.09.051
79. Baumann CL, Aspalter IM, Sharif O, Pichlmair A, Bluml S, Grebien F, Bruckner M, Pasierbek P, Aumayr K, Planyavsky M, et al. CD14 is a coreceptor of Toll-like receptors 7 and 9. J Exp Med 2010;207:2689-701; PMID:21078886; http://dx.doi.org/10.1084/jem.20101111
80. Iwami KI, Matsuguchi T, Masuda A, Kikuchi T, Musikacharoen T, Yoshikai Y. Cutting edge: naturally occurring soluble form of mouse Toll-like receptor 4 inhibits lipopolysaccharide signaling. J Immunol 2000; 165:6682-6; PMID:11120784
81. LeBouder E, Rey-Nores JE, Rushmere NK, Grigorov M, Lawn SD, Affolter M, Griffin GE, Ferrara P, Schiffrin EJ, Morgan BP, et al. Soluble forms of Tolllike receptor (TLR)2 capable of modulating TLR2 signaling are present in human plasma and breast milk. J Immunol 2003; 171:6680-9; PMID:14662871
82. Janssens S, Burns K, Tschopp J, Beyaert R. Regulation of interleukin-1- and lipopolysaccharide-induced NFkappaB activation by alternative splicing of MyD88. Curr Biol 2002; 12:467-71; PMID:11909531
83. Burns K, Janssens S, Brissoni B, Olivos N, Beyaert R, Tschopp J. Inhibition of interleukin 1 receptor/Tolllike receptor signaling through the alternatively spliced, short form of MyD88 is due to its failure to recruit IRAK-4. J Exp Med 2003; 197:263-8; PMID:12538665
84. Wald D, Qin J, Zhao Z, Qian Y, Naramura M, Tian L, Towne J, Sims JE, Stark GR, Li X. SIGIRR, a negative regulator of Toll-like receptor-interleukin 1 receptor signaling. Nat Immunol 2003; 4:920-7; PMID:12925853; http://dx.doi.org/10.1038/ni968
85. Garlanda C, Riva F, Polentarutti N, Buracchi C, Sironi M, De Bortoli M, Muzio M, Bergottini R, Scanziani E, Vecchi A, et al. Intestinal inflammation in mice deficient in Tir8, an inhibitory member of the IL-1 receptor family. Proc Natl Acad Sci U S A 2004;101:3522-6; PMID:14993616; http://dx.doi.org/10.1073/pnas.0308680101
86. Brint EK, Xu D, Liu H, Dunne A, McKenzie AN, O'Neill LA, Liew FY. ST2 is an inhibitor of interleukin 1 receptor and Toll-like receptor 4 signaling and maintains endotoxin tolerance. Nat Immunol 2004; 5:373-9; PMID:15004556; http://dx.doi.org/10.1038/ni1050
87. Diehl GE, Yue HH, Hsieh K, Kuang AA, Ho M, Morici LA, Lenz LL, Cado D, Riley LW, Winoto A. TRAIL-R as a negative regulator of innate immune cell responses. Immunity 2004; 21:877-89; PMID:15589175; http://dx.doi.org/10.1016/j.immuni.2004.11.008
88. Ji S, Sun M, Zheng X, Li L, Sun L, Chen D, Sun Q. Cell-surface localization of Pellino antagonizes Tollmediated innate immune signalling by controlling MyD88 turnover in Drosophila. Nat Commun 2014;5:3458; PMID:24632597; http://dx.doi.org/10.1038/ncomms4458
89. Chuang TH, Ulevitch RJ. Triad3A, an E3 ubiquitinprotein ligase regulating Toll-like receptors. Nat Immunol 2004; 5:495-502; PMID:15107846; http:// dx.doi.org/10.1038/ni1066
90. Shi M, Deng W, Bi E, Mao K, Ji Y, Lin G, Wu X, Tao Z, Li Z, Cai X, et al. TRIM30 alpha negatively regulates TLR-mediated NF-kappa B activation by targeting TAB2 and TAB3 for degradation. Nat Immunol 2008; 9:369-77; PMID:18345001; http:// dx.doi.org/10.1038/ni1577
91. Wang C, Chen T, Zhang J, Yang M, Li N, Xu X, Cao X. The E3 ubiquitin ligase Nrdp1 'preferentially' promotes TLR-mediated production of type I interferon. Nat Immunol 2009; 10:744-52; PMID:19483718; http://dx.doi.org/10.1038/ni.1742
92. Opipari AW, Jr, Boguski MS, Dixit VM. The A20 cDNA induced by tumor necrosis factor alpha encodes a novel type of zinc finger protein. J Biol Chem 1990; 265:14705-8; PMID:2118515
93. Krikos A, Laherty CD, Dixit VM. Transcriptional activation of the tumor necrosis factor alpha-inducible zinc finger protein, A20, is mediated by kappa B elements. J Biol Chem 1992; 267:17971-6; PMID:1381359
94. Boone DL, Turer EE, Lee EG, Ahmad RC, Wheeler MT, Tsui C, Hurley P, Chien M, Chai S, Hitotsumatsu O, et al. The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses. Nat Immunol 2004; 5:1052-60; PMID:15334086; http://dx.doi.org/10.1038/ni1110
95. Shembade N, Ma A, Harhaj EW. Inhibition of NFkappaB signaling by A20 through disruption of ubiquitin enzyme complexes. Science 2010; 327:1135-9; PMID:20185725; http://dx.doi.org/10.1126/science.1182364
96. Wertz IE, O'Rourke KM, Zhou H, Eby M, Aravind L, Seshagiri S, Wu P, Wiesmann C, Baker R, Boone DL, et al. De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling. Nature 2004; 430:694-9; PMID:15258597; http:// dx.doi.org/10.1038/nature02794
97. Shembade N, Harhaj NS, Parvatiyar K, Copeland NG, Jenkins NA, Matesic LE, Harhaj EW. The E3 ligase Itch negatively regulates inflammatory signaling pathways by controlling the function of the ubiquitinediting enzyme A20. Nat Immunol 2008; 9:254-62; PMID:18246070; http://dx.doi.org/10.1038/ni1563
98. Shembade N, Parvatiyar K, Harhaj NS, Harhaj EW. The ubiquitin-editing enzyme A20 requires RNF11 to downregulate NF-kappaB signalling. EMBO J 2009; 28:513-22; PMID:19131965; http://dx.doi. org/10.1038/emboj.2008.285
99. Lee EG, Boone DL, Chai S, Libby SL, Chien M, Lodolce JP, Ma A. Failure to regulate TNF-induced NF-kappaB and cell death responses in A20-deficient mice. Science 2000; 289:2350-4; PMID:11009421
100. Kovalenko A, Chable-Bessia C, Cantarella G, Israel A, Wallach D, Courtois G. The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination. Nature 2003; 424:801-5; PMID:12917691; http://dx.doi.org/10.1038/nature01802
101. Trompouki E, Hatzivassiliou E, Tsichritzis T, Farmer H, Ashworth A, Mosialos G. CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members. Nature 2003;424:793-6; PMID:12917689; http://dx.doi.org/10.1038/nature01803
102. Reiley WW, Zhang M, Jin W, Losiewicz M, Donohue KB, Norbury CC, Sun SC. Regulation of T cell development by the deubiquitinating enzyme CYLD. Nat Immunol 2006; 7:411-7; PMID:16501569; http://dx.doi.org/10.1038/ni1315
103. Reiley WW, Jin W, Lee AJ, Wright A, Wu X, Tewalt EF, Leonard TO, Norbury CC, Fitzpatrick L, Zhang M, et al. Deubiquitinating enzyme CYLD negatively regulates the ubiquitin-dependent kinase Tak1 and prevents abnormal T cell responses. J Exp Med 2007;204:1475-85; PMID:17548520; http://dx.doi.org/10.1084/jem.20062694
104. Friedman CS, O'Donnell MA, Legarda-Addison D, Ng A, Cardenas WB, Yount JS, Moran TM, Basler CF, Komuro A, Horvath CM, et al. The tumour suppressor CYLD is a negative regulator of RIG-I-mediated antiviral response. EMBO Rep 2008; 9:930-6; PMID:18636086; http://dx.doi.org/10.1038/embor.2008.136
105. Lee AJ, Zhou X, Chang M, Hunzeker J, Bonneau RH, Zhou D, Sun SC. Regulation of natural killer T-cell development by deubiquitinase CYLD. EMBO J 2010; 29:1600-12; PMID:20224552; http://dx.doi. org/10.1038/emboj.2010.31
106. Moore CB, Bergstralh DT, Duncan JA, Lei Y, Morrison TE, Zimmermann AG, Accavitti-Loper MA, Madden VJ, Sun L, Ye Z, et al. NLRX1 is a regulator of mitochondrial antiviral immunity. Nature 2008;451:573-7; PMID:18200010; http://dx.doi.org/10.1038/nature06501
107. Allen IC, Moore CB, Schneider M, Lei Y, Davis BK, Scull MA, Gris D, Roney KE, Zimmermann AG, Bowzard JB, et al. NLRX1 protein attenuates inflammatory responses to infection by interfering with the RIG-I-MAVS and TRAF6-NF-kappaB signaling pathways. Immunity 2011; 34:854-65; PMID:21703540; http://dx.doi.org/10.1016/j.immuni.2011.03.026
108. Xia X, Cui J, Wang HY, Zhu L, Matsueda S, Wang Q, Yang X, Hong J, Songyang Z, Chen ZJ, et al. NLRX1 negatively regulates TLR-induced NF-kappaB signaling by targeting TRAF6 and IKK. Immunity 2011; 34:843-53; PMID:21703539; http://dx. doi.org/10.1016/j.immuni.2011.02.022
109. Tattoli I, Carneiro LA, Jehanno M, Magalhaes JG, Shu Y, Philpott DJ, Arnoult D, Girardin SE. NLRX1 is a mitochondrial NOD-like receptor that amplifies NF-kappaB and JNK pathways by inducing reactive oxygen species production. EMBO Rep 2008; 9:293-300; PMID:18219313; http://dx.doi.org/10.1038/sj. embor.401161
110. Lei Y, Wen H, Yu Y, Taxman DJ, Zhang L, Widman DG, Swanson KV, Wen KW, Damania B, Moore CB, et al. The mitochondrial proteins NLRX1 and TUFM form a complex that regulates type I interferon and autophagy. Immunity 2012; 36:933-46; PMID:22749352; http://dx.doi.org/10.1016/j. immuni.2012.03.025
111. Kobayashi KS, van den Elsen PJ. NLRC5: a key regulator of MHC class I-dependent immune responses. Nat Rev Immunol 2012; 12:813-20; PMID:23175229; http://dx.doi.org/10.1038/nri3339
112. Cui J, Zhu L, Xia X, Wang HY, Legras X, Hong J, Ji J, Shen P, Zheng S, Chen ZJ, et al. NLRC5 negatively regulates the NF-kappaB and type I interferon signaling pathways. Cell 2010; 141:483-96; PMID:20434986; http://dx.doi.org/10.1016/j.cell.2010.03.040
113. Benko S, Magalhaes JG, Philpott DJ, Girardin SE. NLRC5 limits the activation of inflammatory pathways. J Immunol 2010; 185:1681-91; PMID:20610642; http://dx.doi.org/10.4049/ jimmunol.0903900
114. Tong Y, Cui J, Li Q, Zou J, Wang HY, Wang RF. Enhanced TLR-induced NF-kappaB signaling and type I interferon responses in NLRC5 deficient mice. Cell Res 2012; 22:822-35; PMID:22473004; http:// dx.doi.org/10.1038/cr.2012.53
115. Kumar H, Pandey S, Zou J, Kumagai Y, Takahashi K, Akira S, Kawai T. NLRC5 deficiency does not influence cytokine induction by virus and bacteria infections. J Immunol 2011; 186:994-1000; PMID:21148033; http://dx.doi.org/10.4049/jimmunol.1002094
116. Staehli F, Ludigs K, Heinz LX, Seguin-Estevez Q, Ferrero I, Braun M, Schroder K, Rebsamen M, Tardivel A, Mattmann C, et al. NLRC5 deficiency selectively impairs MHC class I- dependent lymphocyte killing by cytotoxic T cells. J Immunol 2012; 188:3820-8; PMID:22412192; http://dx. doi.org/10.4049/jimmunol.1102671
117. Schneider M, Zimmermann AG, Roberts RA, Zhang L, Swanson KV, Wen H, Davis BK, Allen IC, Holl EK, Ye Z, et al. The innate immune sensor NLRC3 attenuates Toll-like receptor signaling via modification of the signaling adaptor TRAF6 and transcription factor NF-kappaB. Nat Immunol 2012; 13:823-31; PMID:22863753; http://dx.doi.org/10.1038/ni.2378
118. Anand PK, Malireddi RK, Lukens JR, Vogel P, Bertin J, Lamkanfi M, Kanneganti TD. NLRP6 negatively regulates innate immunity and host defence against bacterial pathogens. Nature 2012; 488:389-93; PMID:22763455; http://dx.doi.org/10.1038/nature11250
119. Kinjyo I, Hanada T, Inagaki-Ohara K, Mori H, Aki D, Ohishi M, Yoshida H, Kubo M, Yoshimura A, et al. SOCS1/JAB is a negative regulator of LPSinduced macrophage activation. Immunity 2002;17:583-91; PMID:12433365
120. Nakagawa R, Naka T, Tsutsui H, Fujimoto M, Kimura A, Abe T, Seki E, Sato S, Takeuchi O, Takeda K, et al. SOCS-1 participates in negative regulation of LPS responses. Immunity 2002; 17:677-87; PMID:12433373
121. Kobayashi K, Hernandez LD, Galan JE, Janeway CA, Jr., Medzhitov R, Flavell RA. IRAK-M is a negative regulator of Toll-like receptor signaling. Cell 2002;110:191-202; PMID:12150927
122. Zhang G, Ghosh S. Negative regulation of toll-like receptor-mediated signaling by Tollip. J Biol Chem 2002; 277:7059-65; PMID:11751856; http://dx.doi. org/10.1074/jbc.M109537200
123. Shenoy AR, Wellington DA, Kumar P, Kassa H, Booth CJ, Cresswell P, MacMicking JD. GBP5 promotes NLRP3 inflammasome assembly and immunity in mammals. Science 2012; 336:481-5; PMID:22461501; http://dx.doi.org/10.1126/science.1217141
124. Subramanian N, Natarajan K, Clatworthy MR,Wang Z, Germain RN. The adaptor MAVS promotes NLRP3 mitochondrial localization and inflammasome activation. Cell 2013; 153:348-61; PMID:23582325; http://dx.doi. org/10.1016/j.cell.2013.02.054
125. Misawa T, Takahama M, Kozaki T, Lee H, Zou J, Saitoh T, Akira S. Microtubule-driven spatial arrangement of mitochondria promotes activation of the NLRP3 inflammasome. Nat Immunol 2013; 14:454-60; PMID:23502856; http://dx.doi.org/10.1038/ ni.2550
126. Juliana C, Fernandes-Alnemri T, Kang S, Farias A, Qin F, Alnemri ES. Non-transcriptional priming and deubiquitination regulate NLRP3 inflammasome activation. J Biol Chem 2012; 287:36617-22; PMID:22948162; http://dx.doi.org/10.1074/jbc.M112.407130
127. Lopez-Castejon G, Luheshi NM, Compan V, High S, Whitehead RC, Flitsch S, Kirov A, Prudovsky I, Swanton E, Brough D. Deubiquitinases regulate the activity of caspase-1 and interleukin-1beta secretion via assembly of the inflammasome. J Biol Chem 2013; 288:2721-33; PMID:23209292; http://dx.doi. org/10.1074/jbc.M112.422238
128. Py BF, Kim MS, Vakifahmetoglu-Norberg H, Yuan J. Deubiquitination of NLRP3 by BRCC3 critically regulates inflammasome activity. Mol Cell 2013; 49:331-8; PMID:23246432; http://dx.doi.org/10.1016/j. molcel.2012.11.009
129. Hu Y, Mao K, Zeng Y, Chen S, Tao Z, Yang C, Sun S, Wu X, Meng G, Sun B. Tripartite-motif protein 30 negatively regulates NLRP3 inflammasome activation by modulating reactive oxygen species production. J Immunol 2010; 185:7699-705; PMID:21048113; http://dx.doi.org/10.4049/jimmunol.1001099
130. Shi CS, Shenderov K, Huang NN, Kabat J, Abu-Asab M, Fitzgerald KA, Sher A, Kehrl JH. Activation of autophagy by inflammatory signals limits IL-1beta production by targeting ubiquitinated inflammasomes for destruction. Nat Immunol 2012; 13:255-63; PMID:22286270; http://dx.doi.org/10.1038/ni.2215
131. Mishra BB, Rathinam VA, Martens GW, Martinot AJ, Kornfeld H, Fitzgerald KA, Sassetti CM. Nitric oxide controls the immunopathology of tuberculosis by inhibiting NLRP3 inflammasome-dependent processing of IL-1beta. Nat Immunol 2013; 14:52-60; PMID:23160153; http://dx.doi.org/10.1038/ni.2474
132. Labbe K, McIntire CR, Doiron K, Leblanc PM, Saleh M. Cellular inhibitors of apoptosis proteins cIAP1 and cIAP2 are required for efficient caspase-1 activation by the inflammasome. Immunity 2011; 35:897-907; PMID:22195745; http://dx.doi.org/10.1016/j.immuni.2011.10.016
133. Qu Y, Misaghi S, Izrael-Tomasevic A, Newton K, Gilmour LL, Lamkanfi M, Louie S, Kayagaki N, Liu J, Kömüves L, et al. Phosphorylation of NLRC4 is critical for inflammasome activation. Nature 2012;490:539-42; PMID:22885697; http://dx.doi.org/10.1038/nature11429
134. Hu Z, Yan C, Liu P, Huang Z, Ma R, Zhang C, Wang R, Zhang Y,Martinon F, Miao D, et al. Crystal structure of NLRC4 reveals its autoinhibition mechanism. Science 2013; 341:172-5; PMID:23765277; http://dx.doi.org/10.1126/science.1236381
135. Gross O, Poeck H, Bscheider M, Dostert C, Hannesschlager N, Endres S, Hartmann G, Tardivel A, Schweighoffer E, Tybulewicz V, et al. Syk kinase signalling couples to the Nlrp3 inflammasome for antifungal host defence. Nature 2009; 459:433-6; PMID:19339971; http://dx.doi.org/10.1038/nature07965
136. Shio MT, Eisenbarth SC, SavariaM, Vinet AF, Bellemare MJ, Harder KW, Sutterwala FS, Bohle DS, Descoteaux A, Flavell RA, et al. Malarial hemozoin activates the NLRP3 inflammasome through Lyn and Syk kinases. PLoS Pathog 2009; 5:e1000559; PMID:19696895; http://dx.doi.org/10.1371/journal.ppat.1000559
137. Hara H, Tsuchiya K, Kawamura I, Fang R, Hernan-dez-Cuellar E, Shen Y, et al. Phosphorylation of the adaptor ASC acts as a molecular switch that controls the formation of speck-like aggregates and inflammasome activity. Nat Immunol 2013; 14:1247-55; PMID:24185614; http://dx.doi.org/10.1038/ni.2749
138. Lu B, Nakamura T, Inouye K, Li J, Tang Y, Lundback P, Valdes-Ferrer SI, Olofsson PS, Kalb T, Roth J, et al. Novel role of PKR in inflammasome activation and HMGB1 release. Nature 2012; 488:670-4; PMID:22801494; http://dx.doi.org/10.1038/nature11290
139. He Y, Franchi L,NunezG.The protein kinase PKRis critical for LPS-induced iNOS production but dispensable for inflammasome activation in macrophages. Eur J Immunol 2013; 43:1147-52; PMID:23401008; http://dx.doi.org/10.1002/eji.201243187
140. Hayakawa S, Shiratori S, Yamato H, Kameyama T, Kitatsuji C, Kashigi F, Goto S, Kameoka S, Fujikura D, Yamada T, et al. ZAPS is a potent stimulator of signaling mediated by the RNA helicase RIG-I during antiviral responses. Nat Immunol 2011; 12:37-44; PMID:21102435; http://dx.doi.org/10.1038/ni.1963
141. Gack MU, Shin YC, Joo CH, Urano T, Liang C, Sun L, Takeuchi O, Akira S, Chen Z, Inoue S, et al. TRIM25 RING-finger E3 ubiquitin ligase is essential for RIG-I-mediated antiviral activity. Nature 2007;446:916-20; PMID:17392790; http://dx.doi.org/10.1038/nature05732
142. Oshiumi H, Matsumoto M, Hatakeyama S, Seya T. Riplet/RNF135, a RING finger protein, ubiquitinates RIG-I to promote interferon-beta induction during the early phase of viral infection. J Biol Chem 2009;284:807-17; PMID:19017631; http://dx.doi.org/10.1074/jbc.M804259200
143. Pauli EK, Chan YK, Davis ME, Gableske S, Wang MK, Feister KF, Gack MU. The ubiquitin-specific protease USP15 promotes RIG-I-mediated antiviral signaling by deubiquitylating TRIM25. Sci Signal 2014; 7:ra3; PMID:24399297; http://dx.doi.org/10.1126/scisignal.2004577
144. Zeng W, Sun L, Jiang X, Chen X, Hou F, Adhikari A, Xu M, Chen ZJ. Reconstitution of the RIG-I pathway reveals a signaling role of unanchored polyubiquitin chains in innate immunity. Cell 2010; 141:315-30; PMID:20403326; http://dx.doi.org/10.1016/j.cell.2010.03.029
145. Peisley A, Wu B, Xu H, Chen ZJ, Hur S. Structural basis for ubiquitin-mediated antiviral signal activation by RIG-I. Nature 2014; 509:110-4; PMID:24590070; http://dx.doi.org/10.1038/nature13140
146. Cui J, Song Y, Li Y, Zhu Q, Tan P, Qin Y, Wang HY, Wang RF. USP3 inhibits type I interferon signaling by deubiquitinating RIG-I-like receptors. Cell Res 2014; 24:400-16; PMID:24366338; http://dx.doi. org/10.1038/cr.2013.170
147. Fan Y, Mao R, Yu Y, Liu S, Shi Z, Cheng J, Zhang H, An L, Zhao Y, Xu X, et al. USP21 negatively regulates antiviral response by acting as a RIG-I deubiquitinase. J Exp Med 2014; 211:313-28; PMID:24493797; http://dx.doi.org/10.1084/jem.20122844
148. Arimoto K, Takahashi H, Hishiki T, Konishi H, Fujita T, Shimotohno K. Negative regulation of the RIG-I signaling by the ubiquitin ligase RNF125. Proc Natl Acad Sci U S A 2007; 104:7500-5; PMID:17460044; http://dx.doi.org/10.1073/pnas.0611551104
149. Chen W, Han C, Xie B, Hu X, Yu Q, Shi L, Wang Q, Li D, Wang J, Zheng P, et al. Induction of Siglec-G by RNA viruses inhibits the innate immune response by promoting RIG-I degradation. Cell 2013;152:467-78; PMID:23374343; http://dx.doi.org/10.1016/j.cell.2013.01.011
150. Gack MU, Nistal-Villan E, Inn KS, Garcia-Sastre A, Jung JU. Phosphorylation-mediated negative regulation of RIG-I antiviral activity. J Virol 2010;84:3220-9; PMID:20071582; http://dx.doi.org/10.1128/JVI.02241-09
151. Nistal-Villan E, Gack MU, Martinez-Delgado G, Maharaj NP, Inn KS, Yang H, Wang R, Aggarwal AK, Jung JU, García-Sastre A. Negative role of RIG-I serine 8 phosphorylation in the regulation of inter-feron-beta production. J Biol Chem 2010;285:20252-61; PMID:20406818; http://dx.doi.org/10.1074/jbc.M109.089912
152. Maharaj NP, Wies E, Stoll A, Gack MU. Conventional protein kinase C-alpha (PKC-alpha) and PKC-beta negatively regulate RIG-I antiviral signal transduction. J Virol 2012; 86:1358-71; PMID:22114345; http://dx.doi.org/10.1128/JVI.06543-11
153. Wies E, Wang MK, Maharaj NP, Chen K, Zhou S, Finberg RW, Gack MU. Dephosphorylation of the RNA sensors RIG-I and MDA5 by the phosphatase PP1 is essential for innate immune signaling. Immunity 2013; 38:437-49; PMID:23499489; http://dx.doi.org/10.1016/j.immuni.2012.11.018
154. Gack MU, Kirchhofer A, Shin YC, Inn KS, Liang C, Cui S, Myong S, Ha T, Hopfner KP, Jung JU. Roles of RIG-I N-terminal tandem CARD and splice variant in TRIM25-mediated antiviral signal transduction. Proc Natl Acad Sci U S A 2008; 105:16743-8; PMID:18948594; http://dx.doi.org/10.1073/pnas.0804947105
155. Diao F, Li S, Tian Y, Zhang M, Xu LG, Zhang Y, Wang RP, Chen D, Zhai Z, Zhong B, et al. Negative regulation of MDA5- but not RIG-I-mediated innate antiviral signaling by the dihydroxyacetone kinase. Proc Natl Acad Sci U S A 2007; 104:11706-11; PMID:17600090; http://dx.doi.org/10.1073/pnas. 0700544104
156. Jiang X, Kinch LN, Brautigam CA, Chen X, Du F, Grishin NV, Chen ZJ. Ubiquitin-induced oligomerization of the RNA sensors RIG-I and MDA5 activates antiviral innate immune response. Immunity 2012;36:959-73; PMID:22705106; http://dx.doi.org/10.1016/j.immuni.2012.03.022
157. Jounai N, Takeshita F, Kobiyama K, Sawano A, Miyawaki A, Xin KQ, Ishii KJ, Kawai T, Akira S, Suzuki K, et al. The Atg5 Atg12 conjugate associates with innate antiviral immune responses. Proc Natl Acad Sci U S A 2007; 104:14050-5; PMID:17709747; http://dx.doi.org/10.1073/pnas. 0704014104
158. You F, Sun H, Zhou X, Sun W, Liang S, Zhai Z, Jiang Z. PCBP2 mediates degradation of the adaptor MAVS via the HECT ubiquitin ligase AIP4. Nat Immunol 2009; 10:1300-8; PMID:19881509; http:// dx.doi.org/10.1038/ni.1815
159. Castanier C, Zemirli N, Portier A, Garcin D, Bidere N, Vazquez A, Arnoult D. MAVS ubiquitination by the E3 ligase TRIM25 and degradation by the proteasome is involved in type I interferon production after activation of the antiviral RIG-I-like receptors. BMC Biol 2012; 10:44; PMID:22626058; http://dx.doi. org/10.1186/1741-7007-10-44
160. Pan Y, Li R, Meng JL, Mao HT, Zhang Y, Zhang J. Smurf2 Negatively Modulates RIG-I-Dependent Antiviral Response by Targeting VISA/MAVS for Ubiquitination and Degradation. J Immunol 2014;192:4758-64; PMID:24729608; http://dx.doi.org/10.4049/jimmunol.1302632
161. Zhong B, Zhang L, Lei C, Li Y, Mao AP, Yang Y, Wang YY, Zhang XL, Shu HB. The ubiquitin ligase RNF5 regulates antiviral responses by mediating degradation of the adaptor protein MITA. Immunity 2009; 30:397-407; PMID:19285439; http://dx.doi. org/10.1016/j.immuni.2009.01.008
162. Tsuchida T, Zou J, Saitoh T, Kumar H, Abe T, Matsuura Y, Kawai T, Akira S. The ubiquitin ligase TRIM56 regulates innate immune responses to intracellular double-stranded DNA. Immunity 2010;33:765-76; PMID:21074459; http://dx.doi.org/10.1016/j.immuni.2010.10.013
163. Zhang J, Hu MM, Wang YY, Shu HB. TRIM32 protein modulates type I interferon induction and cellular antiviral response by targeting MITA/STING protein for K63-linked ubiquitination. J Biol Chem 2012;287:28646-55; PMID:22745133; http://dx.doi.org/10.1074/jbc.M112.362608
164. Zhang L, Mo J, Swanson KV, Wen H, Petrucelli A, Gregory SM, Zhang Z, Schneider M, Jiang Y, Fitzgerald KA, et al. NLRC3, a member of the NLR family of proteins, is a negative regulator of innate immune signaling induced by the DNA sensor STING. Immunity 2014; 40:329-41; PMID:24560620; http://dx. doi.org/10.1016/j.immuni.2014.01.010
165. Konno H, Konno K, Barber GN. Cyclic dinucleotides trigger ULK1 (ATG1) phosphorylation of STING to prevent sustained innate immune signaling. Cell 2013; 155:688-98; PMID:24119841; http://dx.doi. org/10.1016/j.cell.2013.09.049
166. Lin YC, Huang DY, Chu CL, Lin YL, Lin WW. The tyrosine kinase Syk differentially regulates Toll-like receptor signaling downstream of the adaptor molecules TRAF6 and TRAF3. Sci Signal 2013; 6:ra71; PMID:23962979; http://dx.doi.org/10.1126/scisignal.2003973
167. Belgnaoui SM, Paz S, Samuel S, Goulet ML, Sun Q, Kikkert M, Iwai K, Dikic I, Hiscott J, Lin R. Linear ubiquitination of NEMO negatively regulates the interferon antiviral response through disruption of the MAVS-TRAF3 complex. Cell Host Microbe 2012;12:211-22; PMID:22901541; http://dx.doi.org/10.1016/j.chom.2012.06.009
168. Kayagaki N, Phung Q, Chan S, Chaudhari R, Quan C, O'Rourke KM, Eby M, Pietras E, Cheng G, Bazan JF, et al. DUBA: a deubiquitinase that regulates type I interferon production. Science 2007; 318:1628-32; PMID:17991829; http://dx.doi.org/10.1126/science.1145918
169. Peng Y, Xu R, Zheng X. HSCARG Negatively Regulates the Cellular Antiviral RIG-I Like Receptor Signaling Pathway by Inhibiting TRAF3 Ubiquitination via Recruiting OTUB1. PLoS Pathog 2014; 10: e1004041; PMID:24763515; http://dx.doi.org/10.1371/journal.ppat.1004041
170. Nakhaei P, Mesplede T, Solis M, Sun Q, Zhao T, Yang L, Chuang TH, Ware CF, Lin R, Hiscott J. The E3 ubiquitin ligase Triad3A negatively regulates the RIG-I/MAVS signaling pathway by targeting TRAF3 for degradation. PLoS Pathog 2009; 5:e1000650; PMID:19893624; http://dx.doi.org/10.1371/journal.ppat.1000650
171. Zhong B, Liu X, Wang X, Li H, Darnay BG, Lin X, Sun SC, Dong C. Ubiquitin-specific protease 25 regulates TLR4-dependent innate immune responses through deubiquitination of the adaptor protein TRAF3. Sci Signal 2013; 6:ra35; PMID:23674823; http://dx.doi.org/10.1126/scisignal.2003708
172. Chau TL, Gioia R, Gatot JS, Patrascu F, Carpentier I, Chapelle JP, O'Neill L, Beyaert R, Piette J, Chariot A. Are the IKKs and IKK-related kinases TBK1 and IKK-epsilon similarly activated? Trends Biochem Sci 2008; 33:171-80; PMID:18353649; http://dx.doi. org/10.1016/j.tibs.2008.01.002
173. Lei CQ, Zhong B, Zhang Y, Zhang J, Wang S, Shu HB. Glycogen synthase kinase 3beta regulates IRF3 transcription factor-mediated antiviral response via activation of the kinase TBK1. Immunity 2010;33:878-89; PMID:21145761; http://dx.doi.org/10.1016/j.immuni.2010.11.021
174. Li S, Wang L, Berman M, Kong YY, Dorf ME. Mapping a dynamic innate immunity protein interaction network regulating type I interferon production. Immunity 2011; 35:426-40; PMID:21903422; http://dx.doi.org/10.1016/j.immuni.2011.06.014
175. Parvatiyar K, Barber GN, Harhaj EW. TAX1BP1 and A20 inhibit antiviral signaling by targeting TBK1-IKKi kinases. J Biol Chem 2010; 285:14999-5009; PMID:20304918; http://dx.doi.org/10.1074/jbc.M110.109819
176. Gao L, Coope H, Grant S, Ma A, Ley SC, Harhaj EW. ABIN1 protein cooperates with TAX1BP1 and A20 proteins to inhibit antiviral signaling. J Biol Chem 2011; 286:36592-602; PMID:21885437; http://dx.doi.org/10.1074/jbc.M111.283762
177. Cui J, Li Y, Zhu L, Liu D, Songyang Z, Wang HY, Wang RF. NLRP4 negatively regulates type I interferon signaling by targeting the kinase TBK1 for degradation via the ubiquitin ligase DTX4. Nat Immunol 2012; 13:387-95; PMID:22388039; http://dx.doi. org/10.1038/ni.2239
178. Zhang M, Wang L, Zhao X, Zhao K, Meng H, Zhao W, Gao C. TRAF-interacting protein (TRIP) negatively regulates IFN-beta production and antiviral response by promoting proteasomal degradation of TANK-binding kinase 1. J Exp Med 2012; 209:1703-11; PMID:22945920; http://dx.doi.org/10.1084/ jem.20120024
179. Honda K, Taniguchi T. IRFs: master regulators of signalling by Toll-like receptors and cytosolic patternrecognition receptors. Nat Rev Immunol 2006;6:644-58; PMID:16932750; http://dx.doi.org/10.1038/nri1900
180. Yu Y, Wang SE, Hayward GS. The KSHV imme-diate-early transcription factor RTA encodes ubiquitin E3 ligase activity that targets IRF7 for proteosome-mediated degradation. Immunity 2005; 22:59-70; PMID:15664159; http://dx.doi. org/10.1016/j.immuni.2004.11.011
181. Yu Y, Hayward GS. The ubiquitin E3 ligase RAUL negatively regulates type i interferon through ubiquitination of the transcription factors IRF7 and IRF3. Immunity 2010; 33:863-77; PMID:21167755; http://dx.doi.org/10.1016/j.immuni.2010.11.027
182. Wang J, Yang B, Hu Y, Zheng Y, Zhou H, Wang Y, Ma Y, Mao K, Yang L, Lin G, et al. Negative regulation of Nmi on virus-triggered type I IFN production by targeting IRF7. J Immunol 2013; 191:3393-9; PMID:23956435; http://dx.doi.org/10.4049/jimmunol.1300740
183. Higgs R, Ni Gabhann J, Ben Larbi N, Breen EP, Fitzgerald KA, Jefferies CA. The E3 ubiquitin ligase Ro52 negatively regulates IFN-beta production post-pathogen recognition by polyubiquitin-mediated degradation of IRF3. J Immunol 2008; 181:1780-6; PMID:18641315
184. Long L, Deng Y, Yao F, Guan D, Feng Y, Jiang H, Li X, Hu P, Lu X, Wang H, et al. Recruitment of Phosphatase PP2A by RACK1 Adaptor Protein Deactivates Transcription Factor IRF3 and Limits Type I Interferon Signaling. Immunity 2014;40:515-29; PMID:24726876; http://dx.doi.org/10.1016/j.immuni.2014.01.015
185. Clevers H. At the crossroads of inflammation and cancer. Cell 2004; 118:671-4; PMID:15369667; http:// dx.doi.org/10.1016/j.cell.2004.09.005
186. Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, Egan LJ, Kagnoff MF, Karin M. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004; 118:285-96; PMID:15294155; http://dx.doi.org/10.1016/j.cell.2004.07.013
187. Karin M, Greten FR. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 2005; 5:749-59; PMID:16175180; http://dx.doi.org/10.1038/nri1703
188. Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 2006; 124:263-6; PMID:16439202; http:// dx.doi.org/10.1016/j.cell.2006.01.007
189. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, Drake CG, Nakai Y, Isaacs WB, Nelson WG. Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007; 7:256-69; PMID:17384581; http://dx. doi.org/10.1038/nrc2090
190. El-Omar EM, Ng MT, Hold GL. Polymorphisms in Toll-like receptor genes and risk of cancer. Oncogene 2008; 27:244-52; PMID:18176606; http://dx.doi. org/10.1038/sj.onc.1210912
191. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420:860-7; PMID:12490959; http:// dx.doi.org/10.1038/nature01322
192. Lin WW, Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 2007; 117:1175-83; PMID:17476347; http:// dx.doi.org/10.1172/JCI31537
193. Maeda S, Kamata H, Luo JL, Leffert H, Karin M. IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell 2005; 121:977-90; PMID:15989949; http://dx.doi.org/10.1016/j.cell.2005.04.014
194. Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, Gutkovich-Pyest E, Urieli-Shoval S, Galun E, Ben-Neriah Y. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 2004; 431:461-6; PMID:15329734; http:// dx.doi.org/10.1038/nature02924
195. Sun J, Wiklund F, Zheng SL, Chang B, Balter K, Li L, Johansson JE, Li G, Adami HO, Liu W, et al. Sequence variants in Toll-like receptor gene cluster (TLR6-TLR1-TLR10) and prostate cancer risk. J Natl Cancer Inst 2005; 97:525-32; PMID:15812078; http://dx.doi.org/10.1093/jnci/dji070
196. Zheng SL, Augustsson-Balter K, Chang B, Hedelin M, Li L, Adami HO, Bensen J, Li G, Johnasson JE, Turner AR, et al. Sequence variants of toll-like receptor 4 are associated with prostate cancer risk: results from the CAncer Prostate in Sweden Study. Cancer Res 2004; 64:2918-22; PMID:15087412
197. Hua D, Liu MY, Cheng ZD, Qin XJ, Zhang HM, Chen Y, Qin GJ, Liang G, Li JN, Han XF, et al. Small interfering RNA-directed targeting of Toll-like receptor 4 inhibits human prostate cancer cell invasion, survival, and tumorigenicity. Mol Immunol 2009; 46:2876-84; PMID:19643479; http://dx.doi. org/10.1016/j.molimm.2009.06.016
198. Yang H, Zhou H, Feng P, Zhou X, Wen H, Xie X, Shen H, Zhu X. Reduced expression of Toll-like receptor 4 inhibits human breast cancer cells proliferation and inflammatory cytokines secretion. J Exp Clin Cancer Res 2010; 29:92; PMID:20618976; http://dx. doi.org/10.1186/1756-9966-29-92
199. Lowe EL, Crother TR, Rabizadeh S, Hu B, Wang H, Chen S, Shimada K, Wong MH, Michelsen KS, Arditi M. Toll-like receptor 2 signaling protects mice from tumor development in a mouse model of colitisinduced cancer. PLoS One 2010; 5:e13027; PMID:20885960; http://dx.doi.org/10.1371/journal. pone.0013027
200. Matijevic T, Marjanovic M, Pavelic J. Functionally active toll-like receptor 3 on human primary and metastatic cancer cells. Scand J Immunol 2009; 70:18-24; PMID:19522763; http://dx.doi.org/10.1111/j.1365-3083.2009.02262.x
201. Nomi N, Kodama S, Suzuki M. Toll-like receptor 3 signaling induces apoptosis in human head and neck cancer via survivin associated pathway. Oncol Rep 2010; 24:225-31; PMID:20514466
202. Wang H, Rayburn ER, Wang W, Kandimalla ER, Agrawal S, Zhang R. Chemotherapy and chemosensitization of non-small cell lung cancer with a novel immunomodulatory oligonucleotide targeting Tolllike receptor 9. Mol Cancer Ther 2006; 5:1585-92; PMID:16818518; http://dx.doi.org/10.1158/1535-7163.MCT-06-0094
203. Goto Y, Arigami T, Kitago M, Nguyen SL, Narita N, Ferrone S, Morton DL, Irie RF, Hoon DS. Activation of Toll-like receptors 2, 3, and 4 on human melanoma cells induces inflammatory factors. Mol Cancer Ther 2008; 7:3642-53; PMID:19001446; http://dx.doi. org/10.1158/1535-7163.MCT-08-0582
204. Rakoff-Nahoum S, Medzhitov R. Regulation of spontaneous intestinal tumorigenesis through the adaptor protein MyD88. Science 2007; 317:124-7; PMID:17615359; http://dx.doi.org/10.1126/science.1140488
205. Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, Elsharkawy AM, Karin M. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 2007; 317:121-4; PMID:17615358; http://dx.doi.org/10.1126/science.1140485
206. Swann JB, Vesely MD, Silva A, Sharkey J, Akira S, Schreiber RD, Smyth MJ. Demonstration of inflam-mation-induced cancer and cancer immunoediting during primary tumorigenesis. Proc Natl Acad Sci U S A 2008; 105:652-6; PMID:18178624; http://dx. doi.org/10.1073/pnas.0708594105
207. Salcedo R, Worschech A, Cardone M, Jones Y, Gyulai Z, Dai RM, Wang E, Ma W, Haines D, O'hUigin C, et al. MyD88-mediated signaling prevents development of adenocarcinomas of the colon: role of interleukin 18. J Exp Med 2010; 207:1625-36; PMID:20624890; http://dx.doi.org/10.1084/jem.20100199
208. Girardin SE, Boneca IG, Viala J, Chamaillard M, Labigne A, Thomas G, Philpott DJ, Sansonetti PJ. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J Biol Chem 2003; 278:8869-72; PMID:12527755; http://dx.doi. org/10.1074/jbc.C200651200
209. Cho JH. The genetics and immunopathogenesis of inflammatory bowel disease. Nat Rev Immunol 2008;8:458-66; PMID:18500230; http://dx.doi.org/10.1038/nri2340
210. Rehman A, Sina C, GavrilovaO,Hasler R,Ott S, Baines JF, Schreiber S, Rosenstiel P. Nod2 is essential for temporal development of intestinal microbial communities. Gut 2011; 60:1354-62; PMID:21421666; http://dx. doi.org/10.1136/gut.2010.216259
211. Couturier-Maillard A, Secher T, Rehman A, Normand S, De Arcangelis A, Haesler R, Huot L, Grandjean T, Bressenot A, Delanoye-Crespin A, et al. NOD2-mediated dysbiosis predisposes mice to transmissible colitis and colorectal cancer. J Clin Invest 2013; 123:700-11; PMID:23281400; http://dx.doi. org/10.1172/JCI62236
212. Allen IC, TeKippe EM, Woodford RM, Uronis JM, Holl EK, Rogers AB, Herfarth HH, Jobin C, Ting JP. The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer. J Exp Med 2010; 207:1045-56; PMID:20385749; http://dx.doi.org/10.1084/jem.20100050
213. Dupaul-Chicoine J, Yeretssian G, Doiron K, Bergstrom KS, McIntire CR, LeBlanc PM, Meunier C, Turbide C, Gros P, Beauchemin N, et al. Control of intestinal homeostasis, colitis, and colitis-associated colorectal cancer by the inflammatory caspases. Immunity 2010; 32:367-78; PMID: 20226691; http://dx.doi.org/10.1016/j.immuni.2010.02.012
214. Zaki MH, Boyd KL, Vogel P, Kastan MB, Lamkanfi M, Kanneganti TD. The NLRP3 inflammasome protects against loss of epithelial integrity and mortality during experimental colitis. Immunity 2010; 32:379-91; PMID:20303296; http://dx.doi.org/10.1016/j. immuni.2010.03.003
215. Chen GY, Liu M, Wang F, Bertin J, Nunez G. A functional role for Nlrp6 in intestinal inflammation and tumorigenesis. J Immunol 2011; 186:7187-94; PMID:21543645; http://dx.doi.org/10.4049/jimmunol.1100412
216. Normand S, Delanoye-Crespin A, Bressenot A, Huot L, Grandjean T, Peyrin-Biroulet L, Lemoine Y, Hot D, Chamaillard M. Nod-like receptor pyrin domaincontaining protein 6 (NLRP6) controls epithelial selfrenewal and colorectal carcinogenesis upon injury. Proc Natl Acad Sci U S A 2011; 108:9601-6; PMID:21593405; http://dx.doi.org/10.1073/pnas.1100981108
217. Wlodarska M, Thaiss CA, Nowarski R, Henao-Mejia J, Zhang JP, Brown EM, Frankel G, Levy M, Katz MN, Philbrick WM, et al. NLRP6 inflammasome orchestrates the colonic host-microbial interface by regulating goblet cell mucus secretion. Cell 2014;156:1045-59; PMID:24581500; http://dx.doi.org/10.1016/j.cell.2014.01.026
218. Hu B, Elinav E, Huber S, Booth CJ, Strowig T, Jin C, Eisenbarth SC, Flavell RA. Inflammation-induced tumorigenesis in the colon is regulated by caspase-1 and NLRC4. Proc Natl Acad Sci U S A 2010;107:21635-40; PMID:21118981; http://dx.doi.org/10.1073/pnas.1016814108
219. Hou J, Zhou Y, Zheng Y, Fan J, Zhou W, Ng IO, Sun H, Qin L, Qiu S, Lee JM, et al. Hepatic RIG-I predicts survival and interferon-alpha therapeutic response in hepatocellular carcinoma. Cancer Cell 2014; 25:49-63; PMID:24360797; http://dx.doi.org/10.1016/j.ccr.2013.11.011
220. Barbie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, Dunn IF, Schinzel AC, Sandy P, Meylan E, Scholl C, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 2009; 462:108-12; PMID:19847166; http:// dx.doi.org/10.1038/nature08460
221. Kato M, Sanada M, Kato I, Sato Y, Takita J, Takeuchi K, Niwa A, Chen Y, Nakazaki K, Nomoto J, et al. Frequent inactivation of A20 in B-cell lymphomas. Nature 2009; 459:712-6; PMID:19412163; http:// dx.doi.org/10.1038/nature07969
222. Schmitz R, Hansmann ML, Bohle V, Martin-Subero JI, Hartmann S, Mechtersheimer G, Klapper W, Vater I, Giefing M, Gesk S, et al. TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma. J Exp Med 2009; 206:981-9; PMID:19380639; http://dx.doi. org/10.1084/jem.20090528